TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20101851
Drug: Follitropin alpha
Normalized name: follitropin alpha
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin alpha with 25 IU human chorionic gonadotropin (hCG) daily
Study: 15605667
Drug: naproxen 500mg
Normalized name: NAPROXEN 500MG TAB
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 500mg twice daily
Study: 8333639
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg IM atropine
Study: 28869825
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus the Memory Support Intervention (CT + Memory Support)
Study: 28869825
Drug: Cognitive therapy-as-usual
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy-as-usual (CT-as-usual)
Study: 23626461
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg plus Metformin
Study: 18266400
Drug: Alendronic acid
Normalized name: Alendronic Acid
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronic acid 5 mg/day
Study: 18266400
Drug: Risedronic acid
Normalized name: Risedronic acid
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronic acid 2.5 mg/day
Study: 15932834
Drug: Extended regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended regimen of norelgestromin/ethinyl E2 transdermal patch (weekly application for 12 consecutive weeks, 1 patch-free week, and 3 more consecutive weekly applications, n = 158)
Study: 15932834
Drug: Cyclic regimen
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic regimen (4 consecutive cycles of 3 weekly applications and 1 patch-free week, n = 81)
Study: 12792297
Drug: E(2)/NETA (0.025/0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2)/NETA (0.025/0.125 mg/day)
Study: 11126377
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion (HAI) therapy
Study: 11126377
Drug: HAI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI with systemic chemotherapy following hepatic resection
Study: 8971665
Drug: Moxa-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxa-only treatment
Study: 8971665
Drug: Holistic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holistic treatment style
Study: 1459154
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg KLH per month for up to 1 year
Study: 6695853
Drug: Involved field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved field radiotherapy (IF RT) plus six cycles of combination chemotherapy (CT)
Study: 29550383
Drug: BP1001 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP1001 monotherapy (90 mg/m2)
Study: 29550383
Drug: BP1001 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP1001 monotherapy
Study: 29550383
Drug: BP1001 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP1001 plus low-dose cytarabine
Study: 26836781
Drug: A+M (amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: A+M (amoxicillin and metronidazole)
Study: 24625583
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of intramuscular streptomycin
Study: 24625583
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of intramuscular streptomycin
Study: 20214755
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of antiretroviral therapy based on WHO clinical criteria
Study: 17373743
Drug: Sodium butyrate
Normalized name: Sodium butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium butyrate coated tablets (1 gram)
Study: 8562036
Drug: Thymostimulin (TP1)
Normalized name: thymostimulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin (TP1) 1.0 mg/kg
Study: 8562036
Drug: Thymostimulin (TP1)
Normalized name: thymostimulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin (TP1) 2.0 mg/kg
Study: 8562036
Drug: Thymostimulin (TP1)
Normalized name: thymostimulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin (TP1) 0.5 mg/kg
Study: 2653713
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of CTX every 6 hr
Study: 2653713
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of CTX every 8 hr
Study: 2653713
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of CTX every 12 hr
Study: 23835291
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of zoledronic acid (ZA) given 1 week before beginning ADT (arm 1)
Study: 23835291
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of zoledronic acid (ZA) given 6 months after beginning ADT (arm 2)
Study: 23835291
Drug: Monthly administration
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly administration of zoledronic acid (ZA) starting 6 months after beginning ADT for a total of 6 doses (arm 3)
Study: 21812904
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg and 400 mg
Study: 20139548
Drug: Parenteral opioid/sedative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral opioid/sedative (pentazocine/promethazine)
Study: 20139548
Drug: Parenteral opioid/sedative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral opioid/sedative
Study: 12144644
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sodium cromoglycate (SCG) and salbutamol (administered as a nebulized solution)
Study: 12144644
Drug: Salbutamol (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (administered as a nebulized solution)
Study: 12144644
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) (administered as a nebulized solution)
Study: 9502092
Drug: Intra-oral sonography
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-oral sonography
Study: 2568645
Drug: Metaclazepam 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaclazepam 15 mg per day
Study: 2568645
Drug: Diazepam 15
Normalized name: diazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 15 mg per day
Study: 192441
Drug: 5-Fluorouracil (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Fluorouracil (oral or intravenous)
Study: 31538430
Drug: Short-term exposure
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term exposure to PM10 (exceeding 100 μg/m³)
Study: 31538430
Drug: Very short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Very short-term exposure to PM10 (exceeding 100 μg/m³ for 2 hours)
Study: 31538430
Drug: Short-term exposure
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term exposure to PM2.5 (exceeding 50 μg/m³)
Study: 31538430
Drug: Very short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Very short-term exposure to PM2.5 (exceeding 50 μg/m³ for 2 hours)
Study: 15333593
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (COC) (19 subjects)
Study: 9563738
Drug: Zileuton (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton (600 mg, four times daily)
Study: 8169699
Drug: Cephalothin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin (1 g i.v. every 6 h for four doses)
Study: 30925579
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for painful UBCs
Study: 30925579
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment for painless UBCs
Study: 30925579
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment for fractured, nondisplaced and mildly displaced proximal humerus UBCs
Study: 30925579
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment for mildly displaced pathologic humerus shaft fractures
Study: 30925579
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment for severely displaced pathologic proximal humerus fractures
Study: 30925579
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for severely displaced pathologic proximal humerus fractures
Study: 30925579
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for severely displaced humerus shaft fractures
Study: 16642224
Drug: Hepatocyte growth
Normalized name: Dna (human hepatocyte growth factor plasmid pvax1 cdna)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatocyte growth factor (HGF) 80-120 mg daily
Study: 10881805
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (300-mg bolus and 20 mg x kg(‐1) x day(‐1) for 3 days)
Study: 10881805
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (150-mg bolus and 10 mg x kg(‐1) x day(‐1) for 3 days)
Study: 25212080
Drug: MF59‐adjuvanted, trivalent,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59‐adjuvanted, trivalent, influenza vaccine (ATIV)
Study: 25212080
Drug: Non‐adjuvanted, trivalent,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐adjuvanted, trivalent, influenza vaccine (TIV)
Study: 18793546
Drug: Epoetin-beta 6,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-beta 6,000 IU (0.3 ml)
Study: 18793546
Drug: Darbepoetin-alpha 30
Normalized name: Darbepoetin
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin-alpha 30 mg (0.3 ml)
Study: 12150618
Drug: Topical budesonide
Normalized name: budesonide Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical budesonide (256 microg daily)
Study: 31566307
Drug: Nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 150 mg twice daily (UIP-like fibrotic pattern)
Study: 29089019
Drug: Lotilaner (Credelio™)
Normalized name: lotilaner Chewable Tablet [Credelio]
DrugBank: Lotilaner (DB17992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotilaner (Credelio™) at a minimum recommended dose rate of 20 mg/kg
Study: 21368429
Drug: Rabdosia rubescens
Normalized name: Isodon rubescens top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabdosia rubescens aqueous extract, 220 mL once a day for 30 days
Study: 21368429
Drug: Placebo, 220
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 220 mL once a day for 30 days
Study: 19142085
Drug: Carbohydrate‐rich drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate‐rich drink (400 ml) at 6‐7 a.m.
Study: 19142085
Drug: Overnight intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight intravenous 5% glucose infusion (1000 ml)
Study: 15494915
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of coenzyme Q twice daily for 3 months
Study: 3737440
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetaminophen 1000 mg and codeine phosphate 60 mg
Study: 29154277
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg twice a day
Study: 29154277
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg twice a day (monotherapy)
Study: 29154277
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg twice a day (add-on therapy)
Study: 24457999
Drug: beta-alanine (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-alanine (6.4 g/day for 6 weeks)
Study: 24457999
Drug: placebo (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (6.4 g/day for 6 weeks)
Study: 23183517
Drug: n‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFA (eicosapentaenoic and docosahexaenoic acid ethyl esters, 3.0 g/d)
Study: 15823787
Drug: Sequential intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential intervention for physical activity followed by fat intake
Study: 15823787
Drug: Sequential intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential intervention for fat intake followed by physical activity
Study: 11994339
Drug: DHEA (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (30 mg/d if <45 yr of age and 20 mg if >=45 yr of age) for 6 months
Study: 7802305
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with sufentanil and concomitant infusion of sufentanil
Study: 7802305
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with sufentanil and concomitant infusion of saline (control)
Study: 380630
Drug: Multiple intradermal
Normalized name: Skin Test Antigens, Multiple Intradermal Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple intradermal injections of absolute alcohol
Study: 380630
Drug: Water injections
Normalized name: WATER FOR INJECTION
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water injections (control)
Study: 31812227
Drug: IL‐6Rα (interleukin‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐6Rα (interleukin‐6 receptor α chain)
Study: 31778193
Drug: S. aureus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. aureus vaccine trial (Phase 2)
Study: 24140184
Drug: Axitinib titration
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib titration (5 mg twice daily during a 4 week lead-in, then titrated to 7 mg and 10 mg if tolerated)
Study: 24140184
Drug: Non-randomised group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-randomised group (no titration)
Study: 21902287
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine combined with naltrexone
Study: 6731771
Drug: Fast-dissolving oral
Normalized name: melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fast-dissolving oral preparation of oxazepam, administered at least one hour pre-operatively
Study: 27212429
Drug: bOPV (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: bOPV (3 doses)
Study: 27212429
Drug: tOPV (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: tOPV (3 doses)
Study: 27212429
Drug: bOPV +
Approvals — FDA: no, EMA: no, PMDA: no
Description: bOPV + 1 dose IPV
Study: 27212429
Drug: bOPV +
Approvals — FDA: no, EMA: no, PMDA: no
Description: bOPV + 2 doses IPV
Study: 27212429
Drug: IPV (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPV (1 or 2 doses)
Study: 22304891
Drug: Suffocation script
Normalized name: Scomber scriptus flesh
DrugBank: Atlantic mackerel (DB15542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suffocation script condition (CS+) with inhalation of 35% CO(2) as UCS
Study: 22304891
Drug: Neutral script
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral script condition (CS-) with inhalation of room air
Study: 22304891
Drug: Urgency script
Normalized name: Scomber scriptus flesh
DrugBank: Atlantic mackerel (DB15542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urgency script condition (CS-) with inhalation of room air
Study: 17606546
Drug: New diaper‐changing,
Approvals — FDA: no, EMA: no, PMDA: no
Description: New diaper‐changing, hand‐washing, and food‐preparation equipment
Study: 18705977
Drug: High-intensity implementation
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity implementation strategy for intravenous thrombolysis
Study: 18705977
Drug: Regular implementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular implementation strategy for intravenous thrombolysis
Study: 8979328
Drug: Conventional transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional transfusion therapy (retrospective cohort)
Study: 30595357
Drug: PCI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI with new-generation drug-eluting stents (DES)
Study: 21414045
Drug: HVP (5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVP (5-15 g per day)
Study: 19669067
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral group therapy (16 semi-structured sessions)
Study: 31957479
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral group therapy
Study: 11485143
Drug: Colesevelam hydrochloride
Normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam hydrochloride (monotherapy) at doses of 1.5-4.5 g once daily or in two divided doses
Study: 11485143
Drug: Colesevelam hydrochloride
Normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam hydrochloride combined with HMG-CoA reductase inhibitor
Study: 11485143
Drug: Colesevelam hydrochloride
Normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam hydrochloride (monotherapy)
Study: 8097921
Drug: Abecarnil 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abecarnil 20 mg
Study: 8097921
Drug: Abecarnil 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abecarnil 40 mg
Study: 29868998
Drug: Behavioral drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral drug abuse treatment (intervention)
Study: 22943586
Drug: Pulse lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse lavage therapy at 10 to 15 psi pressure
Study: 20533373
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg rhFGF-2 (low-dosage group)
Study: 20533373
Drug: 2.4 mg
Normalized name: pectin 2.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 mg rhFGF-2 (high-dosage group)
Study: 20533373
Drug: Low-dosage group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage group
Study: 20533373
Drug: High-dosage group
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage group
Study: 16422854
Drug: Sildenafil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil plus continuous testosterone undecanoate therapy (TRT) in group 1ST
Study: 16422854
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate therapy (TRT) alone in group 1T
Study: 9801742
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide aqueous pump spray (Rhinocort Aqua) 32 micrograms, 64 micrograms, 128 micrograms, 256 micrograms
Study: 9801742
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide aqueous pump spray (Rhinocort Aqua) 32 micrograms, 128 micrograms, 256 micrograms
Study: 9801742
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide aqueous pump spray (Rhinocort Aqua) 256 micrograms
Study: 9801742
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide aqueous pump spray (Rhinocort Aqua)
Study: 25972527
Drug: Epicatechin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epicatechin (100 mg/d)
Study: 25972527
Drug: Quercetin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (160 mg/d)
Study: 16428266
Drug: H pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: H pylori eradication therapy (group 1, n = 41)
Study: 16428266
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group 2, n = 40)
Study: 1348079
Drug: Recombinant interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant interferon-alpha (1, 3, or 5 million units thrice weekly for 4 or 6 months)
Study: 18312543
Drug: Tolterodine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine (4 mg daily for 6 days)
Study: 16550731
Drug: DOX GITS
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DOX GITS (4 mg/d)
Study: 16550731
Drug: DOX-S4 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOX-S4 (4 mg/d)
Study: 16550731
Drug: DOX-S2 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOX-S2 (2 mg/d)
Study: 12606887
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1200 mg of elemental calcium daily)
Study: 1478293
Drug: Polyadenylic-polyuridylic acid
Normalized name: polyacrylic acid (450000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyadenylic-polyuridylic acid (AU), one i.v. injection of 60 mg (in 50 ml of solution) once a week for 6 weeks